View Older Stories View More Recent Stories
-
RBC Capital on Johnson & Johnson (JNJ): '$5B Opportunity is Progressing'
-
What's next for Johnson and Johnson after third failed attempt to settle talc laws
-
Johnson & Johnson (JNJ) Closes Intra-Cellular Therapies, Inc. (ITCI) Acquisition
-
Johnson & Johnson (JNJ) Sets April 2nd as Expected Closing Date for Intra-Cellular Acquisition
-
Federal Judge Rejects Johnson & Johnson (JNJ) Bankruptcy Strategy
-
TD Cowen on Johnson & Johnson (JNJ): 'TALC Settlement Plan Hits Setback'
-
UBS Reiterates Buy Rating on Johnson & Johnson (JNJ)
-
Johnson & Johnson (JNJ) unit ordered to pay $1.64 billion in HIV drug marketing case
-
Johnson & Johnson (JNJ): RYBREVANT plus LAZCLUZE outperforms osimertinib with a significant and unprecedented OS benefit in patients with EGFR-mutated NSCLC
-
Johnson & Johnson (JNJ) presents new nipocalimab data and real-world research
-
Tevogen Bio (TVGN) Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan
-
Investment commitments in U.S. nears $3 trillion since Trump took office
-
J&J is latest company trying to get on Trump's good side with big U.S. investment
-
J&J is latest company trying to get on Trump's good side with big U.S. investment
-
Johnson & Johnson (JNJ) Increases U.S. Investment to More than $55B Over the Next Four Years
-
Johnson & Johnson (JNJ) Announces RYBREVANT plus LAZCLUZE significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025
-
Johnson & Johnson (JNJ): Nipocalimab, the first and only investigational treatment to be granted U.S. FDA Breakthrough Therapy designation for the treatment of adults with moderate-to-severe Sjögren'
-
How could tariffs shake up the pharma sector?
-
RBC Capital on Johnson & Johnson (JNJ): 'Icotrokinra's +$5B Opportunity is Progressing'
-
Johnson & Johnson (JNJ): Icotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients
-
Guggenheim Downgrades Neumora Therapeutics (NMRA) to Neutral
-
Guggenheim Reiterates Buy Rating on Neumora Therapeutics (NMRA), PT $7
-
Johnson & Johnson (JNJ): TREMFYA subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative
-
Biotech Q4 earnings preview: Goldman Sachs
-
Johnson & Johnson (JNJ): New nipocalimab data published in mAbs journal
-
Johnson & Johnson (JNJ) Puts Stroke Care Business Up For Sale - FT
-
Johnson & Johnson (JNJ) PT Raised to $166 at Guggenheim
-
Johnson & Johnson (JNJ) PT Raised to $166 at Barclays
-
Johnson & Johnson (JNJ) PT Lowered to $158 at Bernstein Amid 'Tough Setup for 2025'
-
Johnson & Johnson (JNJ) PT Lowered to $155 at Stifel
-
Johnson & Johnson (JNJ) PT Lowered to $159 at BofA Securities
-
Goldman Sachs Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
-
Biodexa Pharmaceuticals (BDRX) Appoints Gary A. Shangold as Chief Medical Officer
-
Raymond James Reiterates Outperform Rating on Johnson & Johnson (JNJ)
-
Johnson & Johnson (JNJ) Tops Q4 EPS by 2c; offers 2025 guidance
-
Johnson & Johnson (JNJ) call put ratio 3.5 calls to 1 put with a focus on January 24 weekly 155 calls into quarter results
-
Johnson & Johnson (JNJ) Announces SPRAVATO Approved in the U.S.
-
Johnson & Johnson (JNJ) calls more active than puts into quarter results
-
Johnson & Johnson (JNJ): NDA initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive
-
Morgan Stanley Downgrades Intra-Cellular Therapies (ITCI) to Equalweight
-
Morgan Stanley Reiterates Equalweight Rating on Johnson & Johnson (JNJ)
-
Johnson & Johnson (JNJ) Acquires Intra-Cellular Therapies (ITCI) for $132/sh Cash or $14.6B
-
J&J (JNJ) in Talks to Buy Intra-Cellular (ITCI) - Bloomberg
-
Johnson & Johnson (JNJ) Confirms Temporary Pause of US Eval and Varipulse Cases - Bloomberg
-
Johnson & Johnson's (JNJ) Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease
-
Johnson & Johnson (JNJ) Announces RYBREVANT plus LAZCLUZE show statistically significant and clinically meaningful improvement in overall survival versus osimertinib
-
FDA Approves Celltrion's Steqeyma, Biosimilar to J&J's (JNJ) Stelara
-
This consumer stock is a Top Pick for 2025 at Jefferies
-
Johnson & Johnson (JNJ) Announces FDA Issues CRL For Rybrevant BLA
-
RBC Capital on Johnson & Johnson (JNJ): 'Oncology Portfolio Built for Long-Term Growth'
